Primary adrenal non-Hodgkin lymphoma: a case report and review of the literature by Ram, Nanik et al.
eCommons@AKU
Section of Diabetes, Endocrinology and
Metabolism Department of Medicine
April 2017
Primary adrenal non-Hodgkin lymphoma: a case
report and review of the literature
Nanik Ram
Aga Khan University, nanik.ram@aku.edu
Owais Rashid
Aga Khan University, owais.rashid@aku.edu
Saad Farooq
Aga Khan University, Saad.farooq@aku.edu
Imran Ulhaq
Aga Khan University
Najmul Islam
Aga Khan University, najmul.islam@aku.edu
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_med_diabet_endocrinol_metab
Part of the Endocrinology, Diabetes, and Metabolism Commons
Recommended Citation
Ram, N., Rashid, O., Farooq, S., Ulhaq, I., Islam, N. (2017). Primary adrenal non-Hodgkin lymphoma: a case report and review of the
literature. Journal of Medical Case Reports, 11(1), 108.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_diabet_endocrinol_metab/55
CASE REPORT Open Access
Primary adrenal non-Hodgkin lymphoma: a
case report and review of the literature
Nanik Ram1, Owais Rashid1*, Saad Farooq2, Imran Ulhaq1 and Najmul Islam1
Abstract
Background: Lymphomas are cancers that arise from the white blood cells and have been traditionally divided
into two large subtypes: Hodgkin and non-Hodgkin lymphoma. B-cell lymphoma is the most common subtype of
non-Hodgkin lymphoma; almost 85% of patients with lymphoma have this variant. Lymphomas can potentially
arise from any lymphoid tissue located in the body; however, primary adrenal non-Hodgkin lymphoma is extremely
rare. We report the history, examination findings, and laboratory results of a 50-year-old man diagnosed with a
primary left adrenal diffuse large B-cell lymphoma.
Case presentation: A 50-year-old Pakistani man presented to our hospital with progressively increasing pain and
fullness in the left upper quadrant of his abdomen, generalized weakness, easy fatigability, and decreased appetite of 1.5
months’ duration. On examination, he had a blood pressure of 140/80 mmHg with no postural drop, a pulse rate of 106
beats/minute, and no fever. His past medical history was significant for pulmonary tuberculosis 2 years earlier, for which
he received antituberculous therapy. Computed tomography revealed a heterogeneous enhancing soft tissue density
mass in the left adrenal gland. It measured 7.1 × 5.6 × 9.5 cm. Further laboratory workup revealed the following levels:
sodium 135 mEq/L, potassium 4.5 mEq/L, lactate dehydrogenase 905 IU/L, renin 364 IU/ml, aldosterone 5.79 ng/dl,
dehydroepiandrosterone sulfate 79.20 μg/dl, urinary vanillylmandelic acid 6.4 mg/24 hours, and a low-dose overnight
dexamethasone suppression test result of 3.20 μg/dl. The patient underwent left adrenalectomy. Histopathological test
results showed a diffuse large B-cell lymphoma. Immunohistochemical stains were strongly positive for CD20 and
negative for CD3, CD5, CD10, and cyclin D1. The patient’s Ki-67 (Mib-1) index was approximately 80%. He received a total
of six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (rituximab was not given,
owing to financial constraints) and was routinely followed pre- and postchemotherapy at our hematology clinic with
complete blood count and serum lactate dehydrogenase evaluations. The patient responded to chemotherapy and is
currently doing well.
Conclusions: Primary adrenal lymphoma is an extremely rare but rapidly progressive disease. It generally carries a poor
prognosis, partly because an optimal treatment protocol has not yet been established. Further studies with larger sample
sizes are needed to establish the best treatment option and increase overall survival.
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Background
The American Cancer Society estimated that more than
70,000 new cases of non-Hodgkin lymphoma (NHL)
would be diagnosed in 2016 [1, 2]. Although lymphomas
arise mainly from lymph nodes, primary extranodal
NHL occurs in at least 25% of the cases [3]. The adrenal
gland can be secondarily involved in around 4% of the
patients; however, primary adrenal NHL is extremely
rare and accounts for less than 1% of all NHL cases [4].
Primary adrenal lymphoma (PAL) is histologically
proven lymphoma of one or both adrenal glands in pa-
tients with no prior history of lymphoma. If other organs
or lymph nodes besides the adrenal glands are involved,
the adrenal lesion must be unequivocally dominant [5].
PAL occurs predominantly in males in the sixth to
seventh decades of life. Most commonly, this lymphoma
is a nongerminal center-type diffuse large B-cell lymph-
oma (DLBCL), which is present in 70% to 80% of the
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patients [6]. Patients present with abdominal or lumbar
pain; fever; weight loss; and signs of adrenal insufficiency
such as hypotension, hyponatremia, fatigue, skin hyper-
pigmentation, and vomiting [7]. In occasional instances,
it may also be an incidental finding on imaging studies
obtained for other purposes, and it is frequently bilateral
and bulky at the time of presentation. Several etiological
factors, such as Epstein-Barr virus infection, genetic de-
fects in p53 and c-kit, and immune dysregulation, have
been implicated in the pathogenesis of this disease [5, 7].
Laboratory investigations often show elevated lactate
dehydrogenase (LDH), β2-microglobulin, C-reactive pro-
tein, and ferritinemia, which signify high levels of
inflammation associated with PAL [6].
The prognosis of this condition is generally consid-
ered to be poor because PAL is an aggressive disease
and progresses rapidly. An average 1-year survival as
low as 20% has been reported; however, owing to the
rare nature of this disease, prognostic factors are
difficult to elucidate [5].
Case presentation
A 50-year-old Pakistani man known to have had diabetes
for 21 years presented to our hospital with progressively
increasing pain and fullness in the left upper quadrant of
his abdomen, generalized weakness, easy fatigability, and
decreased appetite of 1.5 months’ duration. He also
complained of nausea and early satiety and had a weight
loss of 8 kg over this period. On examination, he was
found to have a blood pressure of 140/80 mmHg with
no postural drop, a pulse rate of 106 beats/minute, and
no fever. His physical examination was otherwise unre-
markable. His past medical history was significant for
pulmonary tuberculosis 2 years earlier, for which he
received antituberculous therapy.
The patient had initially presented at another univer-
sity hospital 3 weeks earlier. At that time, a laboratory
workup and computed tomography (CT) of the abdo-
men with contrast enhancement were done. Although
the results of his complete blood count and renal func-
tion test were normal, CT of the abdomen showed a het-
erogeneous enhancing soft tissue density mass in the left
adrenal gland. The mass measured 7.1 × 5.6 cm in trans-
verse and anteroposterior diameter, and the craniocaudal
extent of the mass was 9.5 cm. Medially, the mass was
abutting the celiac and superior mesenteric arteries, and
posteroinferiorly, it was bordering the renal vessels.
Paraaortic lymphadenopathy was also present, with the
largest one measuring 1.6 cm (Fig. 1).
Further laboratory workup revealed the following levels:
sodium 135 mEq/L, potassium 4.5 mEq/L, LDH 905 IU/L,
renin 364 IU/ml, aldosterone 5.79 ng/dl, dehydroepian-
drosterone sulfate 79.20 μg/dl, urinary vanillylmandelic
acid 6.4 mg/24 hours, and a low-dose overnight
dexamethasone suppression test result of 3.20 μg/dl. The
patient was referred to our urology clinic for surgical re-
moval of his mass. He underwent a left adrenalectomy at
the urology clinic on 4 March 2016. Histopathological
analysis revealed DLBCL (Figs. 2 and 3). The results of im-
munohistochemical stains were strongly positive for CD20
and negative for CD3, CD5, CD10, and cyclin D1. His Ki-
67 (Mib-1) index was approximately 80% (Figs. 4 and 5).
For further management, the patient was referred to our
hematology clinic and was planned for a rituximab, cyclo-
phosphamide, doxorubicin, vincristine, and prednisone (R-
CHOP) chemotherapy regimen starting on 18 March 2016.
He received a total of six cycles of cyclophosphamide,
Fig. 1 Computed tomography of the patient showing a large left
adrenal mass
Fig. 2 Low-power view of the lesion showing diffuse sheets of
neoplastic cells (hematoxylin and eosin stain)
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doxorubicin, vincristine, and prednisone (CHOP; rituximab
was not given, owing to financial constraints) and was
routinely followed pre- and postchemotherapy at the
hematology clinic with complete blood count and serum
LDH evaluations. Positron emission tomography (PET)
performed on 24 March 2016 showed metabolically active
residual disease over the left adrenal bed. Subcentimetric
fluorodeoxyglucose (FDG) deposits were seen in the pa-
tient’s L5, L2, and T12 vertebrae, suggestive of marrow infil-
tration. No evidence of hypermetabolic nodal, hepatic, or
splenic involvement was appreciated. However, the patient
responded to chemotherapy and is currently doing well. He
gained around 8 kg of weight and is following his routine
daily activities. A recent PET scan revealed that the previ-
ously seen hypermetabolic foci along the left crus, left prox-
imal paraaortic region, and foci of FDG uptake in the
lumbar and thoracic vertebrae were not appreciable. The
patient’s Deauville 5-point scale score was 0 (complete
metabolic response).
Discussion
To the best of our knowledge, this is the first report de-
scribing a case of primary adrenal NHL in Pakistan. Our
patient was a man in his fifth decade of life, which, on
the basis of published literature, is a relatively young age
to have this disease. We treated our patient with a regi-
men of CHOP; rituximab was not included, owing to fi-
nancial constraints. Even without rituximab, our patient
showed a complete response to therapy. Because pri-
mary adrenal NHL is a rare disease, optimal treatment
has not yet been established. CHOP or CHOP-like regi-
mens were traditionally used before the introduction of ri-
tuximab, with generally dismal results (overall survival
between 20% and 50%) [7]. In the largest study to date on
PAL, involving 31 patients given an R-CHOP chemother-
apy regimen, complete remission and overall response
rates were 54.8% and 87.0%, respectively. Surprisingly, no
difference was found in overall survival between unilateral
and bilateral NHL of the adrenal gland [8]. Our patient
also underwent adrenalectomy; however, the two largest
studies to date showed no survival benefit in patients who
underwent adrenalectomy as compared with those who
were treated with chemotherapy alone [6, 8].
In another study involving 28 patients with PAL, 64% of
the patients were treated with a CHOP regimen, 50% with
an R-CHOP regimen, and 18% had chemotherapy with
doxorubicin, cyclophosphamide, vindesine, bleomycin,
and prednisone. The overall survival was 61.6%; however,
it was 100% for those who received autologous stem cell
transplants, which suggests that this may prolong survival
[6]. The Ki-67 index was high in our patient (80%).
Ichikawa et al. reported this index to be greater than 70%
in seven patients with primary adrenal DLBCL. They
treated all of these patients with rituximab-containing
chemotherapy and reported a 2-year survival rate of
57%, although none of the patients died as a result of
Fig. 3 High-power view of the lesion showing large-sized neoplastic
cells with pleomorphic nuclei, variably prominent nucleoli, and scant
cytoplasm. Frequent mitotic figures are also noted (hematoxylin and
eosin stain)
Fig. 4 CD20 immunohistochemical stain (pan-B) is strongly positive
for neoplastic cells
Fig. 5 Ki-67 immunohistochemical stain highlights a markedly raised
proliferative index in the neoplastic lymphoid population
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advancement of lymphoma [9]. These authors suggested
that rituximab-containing chemotherapy with central ner-
vous system (CNS) prophylaxis with methotrexate may be
a good treatment option for primary adrenal NHL. Kim et
al. reported CNS relapses or progression in four patients,
none of whom had received intrathecal prophylaxis [8].
For our patient, we opted for CT as the initial imaging
modality and then confirmed the diagnosis via histology
of the resected adrenal gland. Grigg et al. suggested that
though magnetic resonance imaging and CT findings
can be highly suggestive of NHL, a biopsy should be
done for diagnosis. Staging should involve a PET or gal-
lium scan, and in patients with elevated LDH levels, a
lumbar puncture should also be done [7].
According to the International Prognostic Index (IPI),
our patient was in the low- to intermediate-risk category,
which has an estimated 5-year survival of 51%. However,
this scoring system is not specific to PAL; thus, it may be
inaccurate in predicting overall survival. Kim et al. found
that neither high-risk IPI score nor advanced-stage disease
according to the Ann Arbor system had any impact on
the overall survival; therefore, they suggested a modified
IPI scoring system and a revised staging system, which re-
sulted in significantly improved predictability of overall
survival [9]. The modified scoring and staging criteria may
prove beneficial in risk stratification of patients with pri-
mary adrenal NHL and also guide treatment.
No protocol for specific treatment in cases of a
primary adrenal NHL has yet been established, and mul-
tiple authors have used a combination of modalities,
including surgery and chemotherapy. Ichikawa et al.
argued that perhaps one of the reasons for the poor
prognosis is that many patients were previously treated
with chemotherapy not containing rituximab and did
not receive CNS prophylaxis, which may have decreased
overall survival [9].
Conclusions
PAL is a rare but rapidly progressing disease that should
be treated aggressively. Rituximab-containing chemother-
apy such as R-CHOP has shown promise by increasing
the overall survival of patients with this disease. R-CHOP
combined with CNS prophylaxis and autologous stem cell
transplant may further increase overall survival, but fur-
ther studies with larger sample sizes are needed to estab-
lish the best treatment option and decide whether surgery
and radiation have a role in the management of PAL.
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